1
|
Lee WJ, Oh H, Choi I, Lee K, Shin H, Lee YJ, Park J, Yang YH, Ha GS, Lee DE, Choi KY, Choi E. Differences in Proportion of N-acetyllactosamine and O-acetylated Sialic Acid Have No Significant Effect on the Pharmacokinetics and Biological Activity of Darbepoetin Alfa. BIOTECHNOL BIOPROC E 2022. [DOI: 10.1007/s12257-021-0042-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
2
|
Factors affecting the quality of therapeutic proteins in recombinant Chinese hamster ovary cell culture. Biotechnol Adv 2021; 54:107831. [PMID: 34480988 DOI: 10.1016/j.biotechadv.2021.107831] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2021] [Revised: 06/21/2021] [Accepted: 08/30/2021] [Indexed: 12/17/2022]
Abstract
Chinese hamster ovary (CHO) cells are the most widely used mammalian host cells for the commercial production of therapeutic proteins. Fed-batch culture is widely used to produce therapeutic proteins, including monoclonal antibodies, because of its operational simplicity and high product titer. Despite technical advances in the development of culture media and cell cultures, it is still challenging to maintain high productivity in fed-batch cultures while also ensuring good product quality. In this review, factors that affect the quality attributes of therapeutic proteins in recombinant CHO (rCHO) cell culture, such as glycosylation, charge variation, aggregation, and degradation, are summarized and categorized into three groups: culture environments, chemical additives, and host cell proteins accumulated in culture supernatants. Understanding the factors that influence the therapeutic protein quality in rCHO cell culture will facilitate the development of large-scale, high-yield fed-batch culture processes for the production of high-quality therapeutic proteins.
Collapse
|
3
|
Nguyen NTB, Lin J, Tay SJ, Mariati, Yeo J, Nguyen-Khuong T, Yang Y. Multiplexed engineering glycosyltransferase genes in CHO cells via targeted integration for producing antibodies with diverse complex-type N-glycans. Sci Rep 2021; 11:12969. [PMID: 34155258 PMCID: PMC8217518 DOI: 10.1038/s41598-021-92320-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Accepted: 06/09/2021] [Indexed: 02/05/2023] Open
Abstract
Therapeutic antibodies are decorated with complex-type N-glycans that significantly affect their biodistribution and bioactivity. The N-glycan structures on antibodies are incompletely processed in wild-type CHO cells due to their limited glycosylation capacity. To improve N-glycan processing, glycosyltransferase genes have been traditionally overexpressed in CHO cells to engineer the cellular N-glycosylation pathway by using random integration, which is often associated with large clonal variations in gene expression levels. In order to minimize the clonal variations, we used recombinase-mediated-cassette-exchange (RMCE) technology to overexpress a panel of 42 human glycosyltransferase genes to screen their impact on antibody N-linked glycosylation. The bottlenecks in the N-glycosylation pathway were identified and then released by overexpressing single or multiple critical genes. Overexpressing B4GalT1 gene alone in the CHO cells produced antibodies with more than 80% galactosylated bi-antennary N-glycans. Combinatorial overexpression of B4GalT1 and ST6Gal1 produced antibodies containing more than 70% sialylated bi-antennary N-glycans. In addition, antibodies with various tri-antennary N-glycans were obtained for the first time by overexpressing MGAT5 alone or in combination with B4GalT1 and ST6Gal1. The various N-glycan structures and the method for producing them in this work provide opportunities to study the glycan structure-and-function and develop novel recombinant antibodies for addressing different therapeutic applications.
Collapse
Affiliation(s)
- Ngan T. B. Nguyen
- grid.452198.30000 0004 0485 9218Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| | - Jianer Lin
- grid.452198.30000 0004 0485 9218Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| | - Shi Jie Tay
- grid.452198.30000 0004 0485 9218Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| | - Mariati
- grid.452198.30000 0004 0485 9218Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| | - Jessna Yeo
- grid.452198.30000 0004 0485 9218Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| | - Terry Nguyen-Khuong
- grid.452198.30000 0004 0485 9218Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| | - Yuansheng Yang
- grid.452198.30000 0004 0485 9218Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| |
Collapse
|
4
|
Characterisation of recombinant factor IX before and after GlycoPEGylation. Int J Pharm 2020; 588:119654. [PMID: 32693290 DOI: 10.1016/j.ijpharm.2020.119654] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2020] [Revised: 07/08/2020] [Accepted: 07/13/2020] [Indexed: 12/17/2022]
Abstract
The effect of the GlycoPEGylation process used for prolonging the half-life of recombinant factor IX (rFIX) has no impact on the primary and higher order structure of activated factor IX. Characterisation work performed on recombinant factor IX and on the GlycoPEGylated form of rFIX (N9-GP), confirm that the primary structure as well as the post translational modifications (PTMs) (disulphide bonds, γ-carboxylation, β-hydroxylation, sulphation and O- and N-linked glycan structures) were comparable for rFIX and N9-GP. Three O-linked glycan sites were identified in the activation peptide (Thr159, Thr163 and Thr169), where Thr163 has not been reported previously. For N9-GP, the mono GlycoPEGylation is directed toward one of the two N-linked glycans present at Asn157 and Asn167 in the activation peptide in a one to one ratio. Spectroscopic techniques, such as far and near UV Circular Dichroism studies show comparable secondary and tertiary structures of rFIX and N9-GP. The thermally induced unfolding of rFIX and N9-GP shows that the unfolding temperature is approximately 1 °C higher for N9-GP than that of the rFIX. Furthermore, the pH dependent degradation was reduced due to the GlycoPEGylation of rFIX. GlycoPEGylated rFIX (N9-GP) is used for the manufacturing of Refixia® (nonacog beta pegol, Rebinyn®, Novo Nordisk A/S, Bagsvaerd, Denmark).
Collapse
|
5
|
Wang Y, Yang SH, Brimble MA, Harris PWR. Recent Progress in the Synthesis of Homogeneous Erythropoietin (EPO) Glycoforms. Chembiochem 2020; 21:3301-3312. [DOI: 10.1002/cbic.202000347] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2020] [Revised: 06/29/2020] [Indexed: 11/10/2022]
Affiliation(s)
- Yuxin Wang
- School of Chemical Sciences The University of Auckland 23 Symonds Street Auckland 1010 New Zealand
| | - Sung H. Yang
- School of Chemical Sciences The University of Auckland 23 Symonds Street Auckland 1010 New Zealand
- School of Biological Sciences The University of Auckland 3 A Symonds St Auckland 1010 New Zealand
| | - Margaret A. Brimble
- School of Chemical Sciences The University of Auckland 23 Symonds Street Auckland 1010 New Zealand
- School of Biological Sciences The University of Auckland 3 A Symonds St Auckland 1010 New Zealand
- Maurice Wilkins Centre for Molecular Biodiscovery School of Biological Sciences The University of Auckland Auckland 1010 New Zealand
| | - Paul W. R. Harris
- School of Chemical Sciences The University of Auckland 23 Symonds Street Auckland 1010 New Zealand
- School of Biological Sciences The University of Auckland 3 A Symonds St Auckland 1010 New Zealand
- Maurice Wilkins Centre for Molecular Biodiscovery School of Biological Sciences The University of Auckland Auckland 1010 New Zealand
| |
Collapse
|
6
|
Yehuda S, Padler-Karavani V. Glycosylated Biotherapeutics: Immunological Effects of N-Glycolylneuraminic Acid. Front Immunol 2020; 11:21. [PMID: 32038661 PMCID: PMC6989436 DOI: 10.3389/fimmu.2020.00021] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2019] [Accepted: 01/07/2020] [Indexed: 12/14/2022] Open
Abstract
The emerging field of biotherapeutics provides successful treatments for various diseases, yet immunogenicity and limited efficacy remain major concerns for many products. Glycosylation is a key factor determining the pharmacological properties of biotherapeutics, including their stability, solubility, bioavailability, pharmacokinetics, and immunogenicity. Hence, an increased attention is directed at optimizing the glycosylation properties of biotherapeutics. Currently, most biotherapeutics are produced in non-human mammalian cells in light of their ability to produce human-like glycosylation. However, most mammals produce the sialic acid N-glycolylneuraminic acid (Neu5Gc), while humans cannot due to a specific genetic defect. Humans consume Neu5Gc in their diet from mammalian derived foods (red meat and dairy) and produce polyclonal antibodies against diverse Neu5Gc-glycans. Moreover, Neu5Gc can metabolically incorporate into human cells and become presented on surface or secreted glycans, glycoproteins, and glycolipids. Several studies in mice suggested that the combination of Neu5Gc-containing epitopes and anti-Neu5Gc antibodies could contribute to exacerbation of chronic inflammation-mediated diseases (e.g., cancer, cardiovascular diseases, and autoimmunity). This could potentially become complicated with exposure to Neu5Gc-containing biotherapeutics, bio-devices or xenografts. Indeed, Neu5Gc can be found on various approved and marketed biotherapeutics. Here, we provide a perspective review on the possible consequences of Neu5Gc glycosylation of therapeutic protein drugs due to the limited published evidence of Neu5Gc glycosylation on marketed biotherapeutics and studies on their putative effects on immunogenicity, drug efficacy, and safety.
Collapse
Affiliation(s)
- Sharon Yehuda
- Department of Cell Research and Immunology, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
| | - Vered Padler-Karavani
- Department of Cell Research and Immunology, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
7
|
Cowper B, Lavén M, Hakkarainen B, Mulugeta E. Glycan analysis of erythropoiesis-stimulating agents. J Pharm Biomed Anal 2019; 180:113031. [PMID: 31838284 DOI: 10.1016/j.jpba.2019.113031] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Revised: 12/03/2019] [Accepted: 12/04/2019] [Indexed: 01/13/2023]
Abstract
Erythropoiesis stimulating agents (ESAs) are a group of therapeutic glycoproteins used to treat anaemia caused by chronic kidney disease or chemotherapy. A variety of ESA products are available in the European Union, including innovator, biosimilar and second-generation medicines. Glycosylation is a critical quality attribute of ESA products, as it has a crucial influence upon in vivo biological activity. In this study, a combination of chromatography and mass spectrometry analysis has been used to characterise and compare the glycosylation profiles of five ESA products; Eprex® (epoetin alfa), NeoRecormon® (epoetin beta), Binocrit® (epoetin alfa biosimilar), Silapo (epoetin alfa biosimilar) and Aranesp® (darbepoetin alfa). The methods utilised include mixed-mode anion-exchange/hydrophilic interaction chromatography (AEX/HILIC-MS) for N-glycan identification and quantitation, and HILIC-MS for O-glycan characterisation. The products exhibit notable differences in N- and O-glycosylation, including attributes such as sialic acid occupation, O-acetylation, N-acetyllactosamine extended antennae and sulphated/penta-sialylated N-glycans, which have the potential to cause divergence of therapeutic potencies. The study highlights the need for continued monitoring of ESA product glycosylation, ideally allied to pharmacological data, in order to ensure consistency and therapeutic equivalence between products and enhance our understanding of ESA structure-activity-relationships.
Collapse
Affiliation(s)
- Ben Cowper
- National Institute for Biological Standards & Control (NIBSC), Blanche Lane, South Mimms, Hertfordshire EN6 3QG, United Kingdom.
| | - Martin Lavén
- Swedish Medical Products Agency, Dag Hammarskjölds Väg 42, 752 37 Uppsala, Sweden
| | - Birgit Hakkarainen
- Swedish Medical Products Agency, Dag Hammarskjölds Väg 42, 752 37 Uppsala, Sweden
| | - Ezra Mulugeta
- Swedish Medical Products Agency, Dag Hammarskjölds Väg 42, 752 37 Uppsala, Sweden
| |
Collapse
|
8
|
Smekenov I, Bakhtambayeva M, Bissenbayev K, Saparbayev M, Taipakova S, Bissenbaev AK. Heterologous secretory expression of β-glucosidase from Thermoascus aurantiacus in industrial Saccharomyces cerevisiae strains. Braz J Microbiol 2019; 51:107-123. [PMID: 31776864 DOI: 10.1007/s42770-019-00192-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2018] [Accepted: 11/14/2019] [Indexed: 10/25/2022] Open
Abstract
The use of plant biomass for biofuel production will require efficient utilization of the sugars in lignocellulose, primarily cellobiose, because it is the major soluble by-product of cellulose and acts as a strong inhibitor, especially for cellobiohydrolase, which plays a key role in cellulose hydrolysis. Commonly used ethanologenic yeast Saccharomyces cerevisiae is unable to utilize cellobiose; accordingly, genetic engineering efforts have been made to transfer β-glucosidase genes enabling cellobiose utilization. Nonetheless, laboratory yeast strains have been employed for most of this research, and such strains may be difficult to use in industrial processes because of their generally weaker resistance to stressors and worse fermenting abilities. The purpose of this study was to engineer industrial yeast strains to ferment cellobiose after stable integration of tabgl1 gene that encodes a β-glucosidase from Thermoascus aurantiacus (TaBgl1). The recombinant S. cerevisiae strains obtained in this study secrete TaBgl1, which can hydrolyze cellobiose and produce ethanol. This study clearly indicates that the extent of glycosylation of secreted TaBgl1 depends from the yeast strains used and is greatly influenced by carbon sources (cellobiose or glucose). The recombinant yeast strains showed high osmotolerance and resistance to various concentrations of ethanol and furfural and to high temperatures. Therefore, these yeast strains are suitable for ethanol production processes with saccharified lignocellulose.
Collapse
Affiliation(s)
- Izat Smekenov
- Department of Molecular Biology and Genetics, Faculty of Biology and Biotechnology, Al-Farabi Kazakh National University, Almaty, Kazakhstan, 050040.,Scientific Research Institute of Biology and Biotechnology Problems, Al-Farabi Kazakh National University, Almaty, Kazakhstan, 050040
| | - Marzhan Bakhtambayeva
- Department of Molecular Biology and Genetics, Faculty of Biology and Biotechnology, Al-Farabi Kazakh National University, Almaty, Kazakhstan, 050040.,Scientific Research Institute of Biology and Biotechnology Problems, Al-Farabi Kazakh National University, Almaty, Kazakhstan, 050040
| | - Kudaybergen Bissenbayev
- Scientific Research Institute of Biology and Biotechnology Problems, Al-Farabi Kazakh National University, Almaty, Kazakhstan, 050040.,Nazarbayev Intellectual School, Almaty, Kazakhstan, 050044
| | - Murat Saparbayev
- Gustave Roussy Cancer Campus, CNRS UMR8200, Université Paris-Sud, F-94805, Villejuif Cedex, France
| | - Sabira Taipakova
- Department of Molecular Biology and Genetics, Faculty of Biology and Biotechnology, Al-Farabi Kazakh National University, Almaty, Kazakhstan, 050040.,Scientific Research Institute of Biology and Biotechnology Problems, Al-Farabi Kazakh National University, Almaty, Kazakhstan, 050040
| | - Amangeldy K Bissenbaev
- Department of Molecular Biology and Genetics, Faculty of Biology and Biotechnology, Al-Farabi Kazakh National University, Almaty, Kazakhstan, 050040. .,Scientific Research Institute of Biology and Biotechnology Problems, Al-Farabi Kazakh National University, Almaty, Kazakhstan, 050040.
| |
Collapse
|
9
|
Thorpe R, Grampp G, Kang HN, Knezevic I. Quality assessment and its impact on clinical performance of a biosimilar erythropoietin: A simulated case study. Biologicals 2019; 62:8-15. [PMID: 31668854 PMCID: PMC6863428 DOI: 10.1016/j.biologicals.2019.10.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Accepted: 10/17/2019] [Indexed: 12/03/2022] Open
Abstract
The case study described in this paper was developed for the purpose of training for a better understanding of principles relating especially to a comprehensive evaluation of multiple quality attributes as outlined in the WHO guidelines on evaluation of similar biotherapeutic products. It is also to emphasize the importance of an understanding of the critical quality attributes and a risk assessment of the impact on clinical performance. It was prepared to mimic a real situation in which regulators need to evaluate the differences in quality attributes known to have potential impact on clinical activity. Erythropoietin has been identified as one of the important glycosylated therapeutic proteins and a good example to illustrate how structural characteristics would affect product efficacy and safety. The case study illustrates biosimilarity assessment of a candidate of erythropoietin biosimilar and the important quality attributes that need to be considered in order to understand the importance of structure-function relationships as they contribute to the stepwise evaluation of biosimilarity. This paper reflects the outcomes of the case study exercise and discussion from two WHO implementation workshops held in Ghana (September 2015) and Denmark (July 2017).
Collapse
Affiliation(s)
| | - Gustavo Grampp
- Biotherapeutics Group of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), United Kingdom
| | - Hye-Na Kang
- World Health Organization, Department of Essential Medicines and Health Products, Avenue Appia 20, CH-1211, Geneva, Switzerland.
| | - Ivana Knezevic
- World Health Organization, Department of Essential Medicines and Health Products, Avenue Appia 20, CH-1211, Geneva, Switzerland
| |
Collapse
|
10
|
Lee JR, Choi D, Choi I, Park M, Choi E, Lee YJ, Park J, Yang YH, Ha G, Chul Jin H, Kim KP. Comprehensive Characterization of N‐Glycosylation in Darbepoetin Alfa. B KOREAN CHEM SOC 2019. [DOI: 10.1002/bkcs.11856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Jung Rok Lee
- Department of Applied ChemistryInstitute of Natural Science, Global Center for Pharmaceutical Ingredient Materials, Kyung Hee University Yongin 446‐701 South Korea
- Pharmaceutical Analysis CenterCJ HealthCare R&D Institute, CJ HealthCare Icheon 467‐812 South Korea
| | - Doyoung Choi
- Pharmaceutical Analysis CenterCJ HealthCare R&D Institute, CJ HealthCare Icheon 467‐812 South Korea
| | - Inseong Choi
- Pharmaceutical Analysis CenterCJ HealthCare R&D Institute, CJ HealthCare Icheon 467‐812 South Korea
| | - Mikyung Park
- Pharmaceutical Analysis CenterCJ HealthCare R&D Institute, CJ HealthCare Icheon 467‐812 South Korea
| | - Eunyoung Choi
- Biopharmaceutical Research CenterCJ HealthCare R&D Institute, CJ HealthCare Icheon 467‐812 South Korea
| | - Yoon Jung Lee
- Biopharmaceutical Research CenterCJ HealthCare R&D Institute, CJ HealthCare Icheon 467‐812 South Korea
| | - Jeehye Park
- Biopharmaceutical Research CenterCJ HealthCare R&D Institute, CJ HealthCare Icheon 467‐812 South Korea
| | - Yoo Hee Yang
- Biopharmaceutical Research CenterCJ HealthCare R&D Institute, CJ HealthCare Icheon 467‐812 South Korea
| | - Gyong‐Sik Ha
- Biopharmaceutical Research CenterCJ HealthCare R&D Institute, CJ HealthCare Icheon 467‐812 South Korea
| | - Hong Chul Jin
- Pharmaceutical Analysis CenterCJ HealthCare R&D Institute, CJ HealthCare Icheon 467‐812 South Korea
| | - Kwang Pyo Kim
- Department of Applied ChemistryInstitute of Natural Science, Global Center for Pharmaceutical Ingredient Materials, Kyung Hee University Yongin 446‐701 South Korea
| |
Collapse
|
11
|
Streichert K, Seitz C, Hoffmann E, Boos I, Jelkmann W, Brunner T, Unverzagt C, Rubini M. Synthesis of Erythropoietins Site-Specifically Conjugated with Complex-Type N-Glycans. Chembiochem 2019; 20:1914-1918. [PMID: 30973186 DOI: 10.1002/cbic.201900023] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2019] [Revised: 04/05/2019] [Indexed: 12/14/2022]
Abstract
The biological activity of the glycoprotein hormone erythropoietin (EPO) is dependent mainly on the structure of its N-linked glycans. We aimed to readily attach defined N-glycans to EPO through copper-catalyzed azide alkyne cycloaddition. EPO variants with an alkyne-bearing non-natural amino acid (Plk) at the N-glycosylation sites 24, 38, and 83 were obtained by amber suppression followed by protein purification and refolding. Click conjugation of the alkynyl EPOs with biantennary N-glycan azides provided biologically active site-specifically modified EPO glycoconjugates.
Collapse
Affiliation(s)
- Katharina Streichert
- Department of Organic Chemistry, University of Konstanz, Universitätsstrasse 10, 78464, Konstanz, Germany
| | - Carina Seitz
- Department of Biochemical Pharmacology, University of Konstanz, Universitätsstrasse 10, 78464, Konstanz, Germany
| | - Eugenia Hoffmann
- Department of Organic Chemistry, University of Konstanz, Universitätsstrasse 10, 78464, Konstanz, Germany
| | - Irene Boos
- Department of Bioorganic Chemistry, University of Bayreuth, Universitätsstrasse 30, 95440, Bayreuth, Germany
| | - Wolfgang Jelkmann
- Department of Physiology, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany
| | - Thomas Brunner
- Department of Biochemical Pharmacology, University of Konstanz, Universitätsstrasse 10, 78464, Konstanz, Germany
| | - Carlo Unverzagt
- Department of Bioorganic Chemistry, University of Bayreuth, Universitätsstrasse 30, 95440, Bayreuth, Germany
| | - Marina Rubini
- Department of Organic Chemistry, University of Konstanz, Universitätsstrasse 10, 78464, Konstanz, Germany.,Department of Chemistry, University College Dublin, Stillorgan Road, Belfield, Dublin, 4, Ireland
| |
Collapse
|
12
|
Adamíková J, Antošová M, Polakovič M. Chromatographic purification of recombinant human erythropoietin. Biotechnol Lett 2019; 41:483-493. [PMID: 30810853 DOI: 10.1007/s10529-019-02656-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2019] [Accepted: 02/22/2019] [Indexed: 02/07/2023]
Abstract
Recombinant human erythropoietin is a valuable therapeutic protein used in the treatment of several serious diseases. It exists in different isoforms and is produced by genetically modified mammalian cells such as Chinese hamster ovary or human embryonic kidney cells. As for other biopharmaceutical drugs, a key factor for its successful industrial production is to achieve a high degree of purity and to decrease the content of critical impurities to trace amounts. This goal is achieved in the separation sequence which substantial part is formed by chromatographic steps. Therefore, downstream processing forms an essential part of production costs. This review presents the overview of published separation sequences and, analyzes the use of different types of chromatographic media such as affinity, ion-exchange, reversed-phase, hydrophobic interaction, multimodal, and size-exclusion chromatography adsorbents. Their application is discussed with regard to their place in the purification stages generally denoted as capture, intermediate purification and polishing.
Collapse
Affiliation(s)
- Jana Adamíková
- Department of Chemical and Biochemical Engineering, Faculty of Chemical and Food Technology, Institute of Chemical and Environmental Engineering, Slovak University of Technology, Radlinského 9, 812 37, Bratislava, Slovakia
| | - Monika Antošová
- Department of Chemical and Biochemical Engineering, Faculty of Chemical and Food Technology, Institute of Chemical and Environmental Engineering, Slovak University of Technology, Radlinského 9, 812 37, Bratislava, Slovakia
| | - Milan Polakovič
- Department of Chemical and Biochemical Engineering, Faculty of Chemical and Food Technology, Institute of Chemical and Environmental Engineering, Slovak University of Technology, Radlinského 9, 812 37, Bratislava, Slovakia.
| |
Collapse
|
13
|
Bhat AH, Maity S, Giri K, Ambatipudi K. Protein glycosylation: Sweet or bitter for bacterial pathogens? Crit Rev Microbiol 2019; 45:82-102. [PMID: 30632429 DOI: 10.1080/1040841x.2018.1547681] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Protein glycosylation systems in many bacteria are often associated with crucial biological processes like pathogenicity, immune evasion and host-pathogen interactions, implying the significance of protein-glycan linkage. Similarly, host protein glycosylation has been implicated in antimicrobial activity as well as in promoting growth of beneficial strains. In fact, few pathogens notably modulate host glycosylation machineries to facilitate their survival. To date, diverse chemical and biological strategies have been developed for conjugate vaccine production for disease control. Bioconjugate vaccines, largely being produced by glycoengineering using PglB (the N-oligosaccharyltransferase from Campylobacter jejuni) in suitable bacterial hosts, have been highly promising with respect to their effectiveness in providing protective immunity and ease of production. Recently, a novel method of glycoconjugate vaccine production involving an O-oligosaccharyltransferase, PglL from Neisseria meningitidis, has been optimized. Nevertheless, many questions on defining antigenic determinants, glycosylation markers, species-specific differences in glycosylation machineries, etc. still remain unanswered, necessitating further exploration of the glycosylation systems of important pathogens. Hence, in this review, we will discuss the impact of bacterial protein glycosylation on its pathogenesis and the interaction of pathogens with host protein glycosylation, followed by a discussion on strategies used for bioconjugate vaccine development.
Collapse
Affiliation(s)
- Aadil Hussain Bhat
- a Department of Biotechnology , Indian Institute of Technology Roorkee , Roorkee , Uttarakhand 247667 , India
| | - Sudipa Maity
- a Department of Biotechnology , Indian Institute of Technology Roorkee , Roorkee , Uttarakhand 247667 , India
| | - Kuldeep Giri
- a Department of Biotechnology , Indian Institute of Technology Roorkee , Roorkee , Uttarakhand 247667 , India
| | - Kiran Ambatipudi
- a Department of Biotechnology , Indian Institute of Technology Roorkee , Roorkee , Uttarakhand 247667 , India
| |
Collapse
|
14
|
Simple and Robust N -Glycan Analysis Based on Improved 2-Aminobenzoic Acid Labeling for Recombinant Therapeutic Glycoproteins. J Pharm Sci 2018; 107:1831-1841. [DOI: 10.1016/j.xphs.2018.03.013] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2017] [Revised: 03/01/2018] [Accepted: 03/14/2018] [Indexed: 11/24/2022]
|
15
|
Grampp G, McElroy PL, Camblin G, Pollock A. Structure-Function Relationships for Recombinant Erythropoietins: A Case Study From a Proposed Manufacturing Change With Implications for Erythropoietin Biosimilar Study Designs. J Pharm Sci 2018; 107:1512-1520. [PMID: 29408510 DOI: 10.1016/j.xphs.2018.01.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2017] [Revised: 12/19/2017] [Accepted: 01/08/2018] [Indexed: 11/15/2022]
Abstract
Comparability studies used to assess a proposed manufacturing change for a biological product include sensitive analytical studies to confirm there are no significant differences in structural or functional attributes that may contribute to clinically meaningful changes in efficacy or safety. When a proposed change is relatively complex or when clinically relevant differences between the product before and after the change cannot be ruled out based on analytical studies, nonclinical and clinical bridging studies are generally required to confirm overall comparability. In this study, we report findings from a comparability assessment of epoetin alfa before and after a proposed manufacturing process change. Although differences in glycosylation attributes were observed, these were initially believed to be irrelevant to the product's pharmacology. This assumption was initially supported via nonclinical and clinical pharmacology studies, but a clinically meaningful difference in potency was ultimately observed in a phase 3 clinical study conducted in a sensitive patient population using a sensitive study design. These results indicate that the nonclinical assessments of structure-function relationships were insufficiently sensitive to identify clinically relevant differences resulting from differences in the glycosylation profile. This case study highlights important findings that may be relevant in the development of biosimilar epoetin alfa products.
Collapse
|
16
|
Glyco-Engineering of Plant-Based Expression Systems. ADVANCES IN BIOCHEMICAL ENGINEERING/BIOTECHNOLOGY 2018; 175:137-166. [PMID: 30069741 DOI: 10.1007/10_2018_76] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Most secreted proteins in eukaryotes are glycosylated, and after a number of common biosynthesis steps the glycan structures mature in a species-dependent manner. Therefore, human therapeutic proteins produced in plants often carry plant-like rather than human-like glycans, which can affect protein stability, biological function, and immunogenicity. The glyco-engineering of plant-based expression systems began as a strategy to eliminate plant-like glycans and produce human proteins with authentic or at least compatible glycan structures. The precise replication of human glycans is challenging, owing to the absence of a pathway in plants for the synthesis of sialylated proteins and the necessary precursors, but this can now be achieved by the coordinated expression of multiple human enzymes. Although the research community has focused on the removal of plant glycans and their replacement with human counterparts, the presence of plant glycans on proteins can also provide benefits, such as boosting the immunogenicity of some vaccines, facilitating the interaction between therapeutic proteins and their receptors, and increasing the efficacy of antibody effector functions. Graphical Abstract Typical structures of native mammalian and plant glycans with symbols indicating sugar residues identified by their short form and single-letter codes. Both glycans contain fucose, albeit with different linkages.
Collapse
|
17
|
Uversky VN, Redwan EM. Erythropoietin and co.: intrinsic structure and functional disorder. MOLECULAR BIOSYSTEMS 2017; 13:56-72. [PMID: 27833947 DOI: 10.1039/c6mb00657d] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Erythropoietin (Epo) is a heavily glycosylated protein, with its main function being related to erythropoiesis, where it controls red blood cell production via interaction with the Epo receptor (EpoR). It also plays a number of important roles in various hormonal, growth factor, and cytokine pathways. These roles are defined by Epo partners, such as the homodimeric (EpoR)2 receptor, the heterodimeric EpoR/βCR receptor and hypoxia inducing factor (HIF). Although the main structural features of both Epo and EpoR are conserved in vertebrates, the secretion sites of Epo in mammals are different from those in other vertebrates. Both biosynthetic and synthetic analogues of this protein are available on the market. Several side effects, such as pure red cells aplaisa, increase the rate of cancer-related death in patients treated with recombinant Epo. The multifunctionality of Epo and the ability of this protein to serve as a hormone, a cytokine, and a growth factor suggest the presence of functional disorder, which is a typical "structural" feature of moonlighting proteins. The goal of this article is to evaluate the roles of intrinsic disorder in the functions of Epo and its primary interactors, EpoR, βCR, and HIF-1α.
Collapse
Affiliation(s)
- Vladimir N Uversky
- Department of Biological Sciences, Faculty of Sciences, King Abdulaziz University, P.O. Box 80203, Jeddah, Saudi Arabia. and Laboratory of Structural Dynamics, Stability and Folding of Proteins, Institute of Cytology, Russian Academy of Sciences, St. Petersburg, Russia and Department of Molecular Medicine and USF Health Byrd Alzheimer's Research Institute, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
| | - Elrashdy M Redwan
- Department of Biological Sciences, Faculty of Sciences, King Abdulaziz University, P.O. Box 80203, Jeddah, Saudi Arabia. and Therapeutic and Protective Proteins Laboratory, Protein Research Department, Genetic Engineering and Biotechnology Research Institute, City for Scientific Research and Technology Applications, New Borg EL-Arab 21934, Alexandria, Egypt
| |
Collapse
|
18
|
Falck D, Haberger M, Plomp R, Hook M, Bulau P, Wuhrer M, Reusch D. Affinity purification of erythropoietin from cell culture supernatant combined with MALDI-TOF-MS analysis of erythropoietin N-glycosylation. Sci Rep 2017; 7:5324. [PMID: 28706253 PMCID: PMC5509673 DOI: 10.1038/s41598-017-05641-1] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2016] [Accepted: 06/01/2017] [Indexed: 12/18/2022] Open
Abstract
Erythropoietin (EPO) is a heavily glycosylated hormone whose recombinant forms are used for treatment of anaemia. EPO glycosylation is important for its pharmacological properties. An analytical workflow, which can determine EPO glycosylation in an accurate and high-throughput fashion from cell culture supernatant (CCS) in approximately 24 h, offers the possibility to follow changes during production. To address this challenge, we present a complete workflow consisting of protein purification, glycan release, sialic acid derivatization, solid phase extraction, matrix-assisted laser desorption/ionization - mass spectrometry (MALDI-MS) analysis and MassyTools data processing. EPO purification from CCS by anti-EPO antibody coupled Sepharose beads yielded excellent purity with acceptable recovery and was free of glycoform bias. Glycosylation profiles obtained by MALDI-MS were highly comparable to those obtained with an established capillary gel electrophoresis–laser induced fluorescence method. Our method delivers accurate results for the analysis of changes of important glycosylation parameters, such as sialylation and number of N-acetyllactosamine units, for the time course of a fermentation. We could resolve differences in glycosylation between several CCS samples.
Collapse
Affiliation(s)
- David Falck
- Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands.
| | - Markus Haberger
- Pharma Biotech Development Penzberg, Roche Diagnostics GmbH, 82377, Penzberg, Germany
| | - Rosina Plomp
- Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands
| | - Michaela Hook
- Pharma Biotech Development Penzberg, Roche Diagnostics GmbH, 82377, Penzberg, Germany
| | - Patrick Bulau
- Pharma Biotech Development Penzberg, Roche Diagnostics GmbH, 82377, Penzberg, Germany
| | - Manfred Wuhrer
- Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands
| | - Dietmar Reusch
- Pharma Biotech Development Penzberg, Roche Diagnostics GmbH, 82377, Penzberg, Germany
| |
Collapse
|
19
|
Okano M, Sato M, Kageyama S. Mass spectrometric characterisation of darbepoetin alfa biosimilars withC-terminal arginine residues. Drug Test Anal 2016; 8:1138-1146. [DOI: 10.1002/dta.2102] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2016] [Revised: 09/26/2016] [Accepted: 09/30/2016] [Indexed: 12/18/2022]
Affiliation(s)
- Masato Okano
- Anti-Doping Laboratory; LSI Medience Corporation; Tokyo Japan
| | - Mitsuhiko Sato
- Anti-Doping Laboratory; LSI Medience Corporation; Tokyo Japan
| | - Shinji Kageyama
- Anti-Doping Laboratory; LSI Medience Corporation; Tokyo Japan
| |
Collapse
|
20
|
Varki A. Biological roles of glycans. Glycobiology 2016; 27:3-49. [PMID: 27558841 PMCID: PMC5884436 DOI: 10.1093/glycob/cww086] [Citation(s) in RCA: 1433] [Impact Index Per Article: 179.1] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2016] [Revised: 08/15/2016] [Accepted: 08/16/2016] [Indexed: 02/07/2023] Open
Abstract
Simple and complex carbohydrates (glycans) have long been known to play major metabolic, structural and physical roles in biological systems. Targeted microbial binding to host glycans has also been studied for decades. But such biological roles can only explain some of the remarkable complexity and organismal diversity of glycans in nature. Reviewing the subject about two decades ago, one could find very few clear-cut instances of glycan-recognition-specific biological roles of glycans that were of intrinsic value to the organism expressing them. In striking contrast there is now a profusion of examples, such that this updated review cannot be comprehensive. Instead, a historical overview is presented, broad principles outlined and a few examples cited, representing diverse types of roles, mediated by various glycan classes, in different evolutionary lineages. What remains unchanged is the fact that while all theories regarding biological roles of glycans are supported by compelling evidence, exceptions to each can be found. In retrospect, this is not surprising. Complex and diverse glycans appear to be ubiquitous to all cells in nature, and essential to all life forms. Thus, >3 billion years of evolution consistently generated organisms that use these molecules for many key biological roles, even while sometimes coopting them for minor functions. In this respect, glycans are no different from other major macromolecular building blocks of life (nucleic acids, proteins and lipids), simply more rapidly evolving and complex. It is time for the diverse functional roles of glycans to be fully incorporated into the mainstream of biological sciences.
Collapse
Affiliation(s)
- Ajit Varki
- Departments of Medicine and Cellular & Molecular Medicine, Glycobiology Research and Training Center, University of California at San Diego, La Jolla, CA 92093-0687, USA
| |
Collapse
|
21
|
Monroe DM, Jenny RJ, Van Cott KE, Buhay S, Saward LL. Characterization of IXINITY® (Trenonacog Alfa), a Recombinant Factor IX with Primary Sequence Corresponding to the Threonine-148 Polymorph. Adv Hematol 2016; 2016:7678901. [PMID: 26997955 PMCID: PMC4779506 DOI: 10.1155/2016/7678901] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2015] [Accepted: 01/14/2016] [Indexed: 11/17/2022] Open
Abstract
The goal of these studies was to extensively characterize the first recombinant FIX therapeutic corresponding to the threonine-148 (Thr-148) polymorph, IXINITY (trenonacog alfa [coagulation factor IX (recombinant)]). Gel electrophoresis, circular dichroism, and gel filtration were used to determine purity and confirm structure. Chromatographic and mass spectrometry techniques were used to identify and quantify posttranslational modifications. Activity was assessed as the ability to activate factor X (FX) both with and without factor VIIIa (FVIIIa) and in a standard clotting assay. All results were consistent across multiple lots. Trenonacog alfa migrated as a single band on Coomassie-stained gels; activity assays were normal and showed <0.002 IU of activated factor IX (FIXa) per IU of FIX. The molecule has >97% γ-carboxylation and underwent the appropriate structural change upon binding calcium ions. Trenonacog alfa was activated normally with factor XIa (FXIa); once activated it bound to FVIIIa and FXa. When activated to FIXa, it was inhibited efficiently by antithrombin. Glycosylation patterns were similar to plasma-derived FIX with sialic acid content consistent with the literature reports of good pharmacokinetic performance. These studies have shown that trenonacog alfa is a highly pure product with a primary sequence and posttranslational modifications consistent with the common Thr-148 polymorphism of plasma-derived FIX.
Collapse
Affiliation(s)
- Dougald M. Monroe
- School of Medicine, Department of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Richard J. Jenny
- Haematologic Technologies, Incorporated, Essex Junction, VT 05452, USA
| | - Kevin E. Van Cott
- Department of Chemical and Biomolecular Engineering, University of Nebraska-Lincoln, Lincoln, NE 68588, USA
| | - Shelly Buhay
- Biosciences Division, Emergent BioSolutions Incorporated, Winnipeg, MB, Canada R3T 5Y3
| | - Laura L. Saward
- Biosciences Division, Emergent BioSolutions Incorporated, Winnipeg, MB, Canada R3T 5Y3
- University of Manitoba, Winnipeg, MB, Canada R3T 2N2
| |
Collapse
|
22
|
Meininger M, Stepath M, Hennig R, Cajic S, Rapp E, Rotering H, Wolff M, Reichl U. Sialic acid-specific affinity chromatography for the separation of erythropoietin glycoforms using serotonin as a ligand. J Chromatogr B Analyt Technol Biomed Life Sci 2016; 1012-1013:193-203. [DOI: 10.1016/j.jchromb.2016.01.005] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Revised: 12/13/2015] [Accepted: 01/05/2016] [Indexed: 10/22/2022]
|
23
|
Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products. J Pharm Sci 2016; 105:542-550. [DOI: 10.1016/j.xphs.2015.10.019] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2015] [Revised: 09/24/2015] [Accepted: 10/09/2015] [Indexed: 12/19/2022]
|
24
|
Salgado ER, Montesino R, Jiménez SP, González M, Hugues F, Cabezas OI, Maura-Perez R, Saavedra P, Lamazares E, Salas-Burgos A, Vera JC, Sánchez O, Toledo JR. Post-translational modification of a chimeric EPO-Fc hormone is more important than its molecular size in defining its in vivo hematopoietic activity. Biochim Biophys Acta Gen Subj 2015; 1850:1685-93. [PMID: 25960389 DOI: 10.1016/j.bbagen.2015.04.012] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2015] [Revised: 04/28/2015] [Accepted: 04/29/2015] [Indexed: 10/23/2022]
Abstract
BACKGROUND Recombinant erythropoietin (EPO) has been marketed as biopharmaceutical for anemia and chronic renal failure. Long-acting EPO variants that aimed at achieving less frequent dosing have been generated, either by the addition of glycosylation sites or increasing its molecular weight. METHODS The hEPO cDNA linked to the human IgG Fc fragment was cloned as a single codifying gene on the pAdtrack-CMV vector, yielding the recombinant adenoviral genome. For in vitro and in vivo expression assays cervical cancer cell line (SiHa) and nulliparous goats were used, respectively. The hematopoietic activity of EPO-Fc, expressed as the differential increment of hematocrit was evaluated in B6D2F1 mice. NP-HPLC of the 2AB-labeled N-glycan was carried out to profile analysis. RESULTS The direct transduction of mammary secretory cells with adenoviral vector is a robust methodology to obtain high levels of EPO of up to 3.5mg/mL in goat's milk. SiHa-derived EPO-Fc showed significant improvement in hematopoietic activity compared to the commercial hEPO counterpart or with the homologous milk-derived EPO-Fc. The role of the molecular weight seemed to be important in enhancing the hematopoietic activity of SiHa-derived EPO-Fc. However, the lack of sialylated multi-antennary glycosylation profile in milk-derived EPO-Fc resulted in lower biological activity. CONCLUSIONS The low content of tri- or tetra-antennary sialylated N-glycans linked to the chimeric EPO-Fc hormone, expressed in the goat mammary gland epithelial cells, defined its in vivo hematopoietic activity. GENERAL SIGNIFICANCE The sialylated N-glycan content plays a more significant role in the in vivo biological activity of hEPO than its increased molecular weight.
Collapse
Affiliation(s)
- Emilio R Salgado
- Biotechnology and Biopharmaceuticals Laboratory, Department of Physiopathology, School of Biological Sciences, Universidad de Concepción, Victor Lamas 1290, P.O. Box 160C, Concepción, Chile
| | - Raquel Montesino
- Biotechnology and Biopharmaceuticals Laboratory, Department of Physiopathology, School of Biological Sciences, Universidad de Concepción, Victor Lamas 1290, P.O. Box 160C, Concepción, Chile
| | - Sivana P Jiménez
- Biotechnology and Biopharmaceuticals Laboratory, Department of Physiopathology, School of Biological Sciences, Universidad de Concepción, Victor Lamas 1290, P.O. Box 160C, Concepción, Chile
| | - Mauricio González
- Biotechnology and Biopharmaceuticals Laboratory, Department of Physiopathology, School of Biological Sciences, Universidad de Concepción, Victor Lamas 1290, P.O. Box 160C, Concepción, Chile
| | - Florence Hugues
- Clinical Sciences Department, School of Veterinary Sciences, Universidad de Concepción, Avenida Vicente Méndez 595, Chillan, Chile
| | - Oscar I Cabezas
- Clinical Sciences Department, School of Veterinary Sciences, Universidad de Concepción, Avenida Vicente Méndez 595, Chillan, Chile
| | - Rafael Maura-Perez
- Biotechnology and Biopharmaceuticals Laboratory, Department of Physiopathology, School of Biological Sciences, Universidad de Concepción, Victor Lamas 1290, P.O. Box 160C, Concepción, Chile
| | - Paulina Saavedra
- Biotechnology and Biopharmaceuticals Laboratory, Department of Physiopathology, School of Biological Sciences, Universidad de Concepción, Victor Lamas 1290, P.O. Box 160C, Concepción, Chile
| | - Emilio Lamazares
- Biotechnology and Biopharmaceuticals Laboratory, Department of Physiopathology, School of Biological Sciences, Universidad de Concepción, Victor Lamas 1290, P.O. Box 160C, Concepción, Chile
| | - Alexis Salas-Burgos
- Department of Pharmacology, School of Biological Sciences, Universidad de Concepción, Victor Lamas 1290, P.O. Box 160C, Concepción, Chile
| | - Juan C Vera
- Biotechnology and Biopharmaceuticals Laboratory, Department of Physiopathology, School of Biological Sciences, Universidad de Concepción, Victor Lamas 1290, P.O. Box 160C, Concepción, Chile
| | - Oliberto Sánchez
- Department of Pharmacology, School of Biological Sciences, Universidad de Concepción, Victor Lamas 1290, P.O. Box 160C, Concepción, Chile
| | - Jorge R Toledo
- Biotechnology and Biopharmaceuticals Laboratory, Department of Physiopathology, School of Biological Sciences, Universidad de Concepción, Victor Lamas 1290, P.O. Box 160C, Concepción, Chile.
| |
Collapse
|
25
|
|
26
|
Meehl MA, Stadheim TA. Biopharmaceutical discovery and production in yeast. Curr Opin Biotechnol 2014; 30:120-7. [PMID: 25014890 DOI: 10.1016/j.copbio.2014.06.007] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2014] [Revised: 05/15/2014] [Accepted: 06/08/2014] [Indexed: 01/02/2023]
Abstract
The selection of an expression platform for recombinant biopharmaceuticals is often centered upon suitable product titers and critical quality attributes, including post-translational modifications. Although notable differences between microbial, yeast, plant, and mammalian host systems exist, recent advances have greatly mitigated any inherent liabilities of yeasts. Yeast expression platforms are important to both the supply of marketed biopharmaceuticals and the pipelines of novel therapeutics. In this review, recent advances in yeast-based expression of biopharmaceuticals will be discussed. The advantages of using glycoengineered yeast as a production host and in the discovery space will be illustrated. These advancements, in turn, are transforming yeast platforms from simple production systems to key technological assets in the discovery and selection of biopharmaceutical lead candidates.
Collapse
Affiliation(s)
- Michael A Meehl
- GlycoFi, Biologics Research, Merck & Co., Inc., 16 Cavendish Court, Lebanon, NH 03766, USA
| | - Terrance A Stadheim
- GlycoFi, Biologics Research, Merck & Co., Inc., 16 Cavendish Court, Lebanon, NH 03766, USA.
| |
Collapse
|
27
|
Optimization of Dynamic Binding Capacity of Anion Exchange Chromatography Media for Recombinant Erythropoietin Purification. IRANIAN JOURNAL OF BIOTECHNOLOGY 2014. [DOI: 10.5812/ijb.17352] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
28
|
Hashii N, Harazono A, Kuribayashi R, Takakura D, Kawasaki N. Characterization of N-glycan heterogeneities of erythropoietin products by liquid chromatography/mass spectrometry and multivariate analysis. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2014; 28:921-932. [PMID: 24623697 DOI: 10.1002/rcm.6858] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/18/2013] [Revised: 01/26/2014] [Accepted: 01/26/2014] [Indexed: 06/03/2023]
Abstract
RATIONALE Glycan heterogeneity on recombinant human erythropoietin (rEPO) product is considered to be one of the critical quality attributes, and similarity tests of glycan heterogeneities are required in the manufacturing process changes and developments of biosimilars. A method for differentiating highly complex and diverse glycosylations is needed to evaluate comparability and biosimilarity among rEPO batches and products manufactured by different processes. METHODS The glycan heterogeneities of nine rEPO products (four innovator products and five biosimilar products) were distinguished by multivariate analysis (MVA) using the peak area ratios of each glycan to the total peak area of glycans in mass spectra obtained by liquid chromatography/mass spectrometry (LC/MS) of N-glycans from rEPOs. RESULTS Principal component analysis (PCA) using glycan profiles obtained by LC/MS proved to be a useful method for differentiating glycan heterogeneities among nine rEPOs. Using PC values as indices, we were able to visualize and digitalize the glycan heterogeneities of each rEPO. The characteristic glycans of each rEPO were also successfully identified by orthogonal partial least-squares discrimination analysis (OPLS-DA), an MVA method, using the glycan profile data. CONCLUSIONS PCA values were useful for evaluating the relative differences among the glycan heterogeneities of rEPOs. The characteristic glycans that contributed to the differentiation were also successfully identified by OPLS-DA. PCA and OPLS-DA based on mass spectrometric data are applicable for distinguishing glycan heterogeneities, which are virtually indistinguishable on rEPO products.
Collapse
Affiliation(s)
- Noritaka Hashii
- Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo, 158-8501, Japan
| | | | | | | | | |
Collapse
|
29
|
Abstract
Synthetic biology provides numerous great opportunities for chemical engineers in the development of new processes for large-scale production of biofuels, value-added chemicals, and protein therapeutics. However, challenges across all scales abound. In particular, the modularization and standardization of the components in a biological system, so-called biological parts, remain the biggest obstacle in synthetic biology. In this perspective, we will discuss the main challenges and opportunities in the rapidly growing synthetic biology field and the important roles that chemical engineers can play in its advancement.
Collapse
Affiliation(s)
- Yunzi Luo
- Department of Chemical and Biomolecular Engineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801, United States
| | | | | |
Collapse
|
30
|
Jez J, Castilho A, Grass J, Vorauer-Uhl K, Sterovsky T, Altmann F, Steinkellner H. Expression of functionally active sialylated human erythropoietin in plants. Biotechnol J 2013; 8:371-82. [PMID: 23325672 PMCID: PMC3601435 DOI: 10.1002/biot.201200363] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2012] [Revised: 12/10/2012] [Accepted: 01/11/2013] [Indexed: 12/21/2022]
Abstract
Recombinant human erythropoietin (rhEPO), a glycohormone, is one of the leading biopharmaceutical products. The production of rhEPO is currently restricted to mammalian cell expression systems because of rhEPO's highly complex glycosylation pattern, which is a major determinant for drug-efficacy. Here we evaluate the ability of plants to produce different glycoforms of rhEPO. cDNA constructs were delivered to Nicotiana benthamiana (N. benthamiana) and transiently expressed by a viral based expression system. Expression levels up to 85 mg rhEPO/kg fresh leaf material were achieved. Moreover, co-expression of rhEPO with six mammalian genes required for in planta protein sialylation resulted in the synthesis of rhEPO decorated mainly with bisialylated N-glycans (NaNa), the most abundant glycoform of circulating hEPO in patients with anemia. A newly established peptide tag (ELDKWA) fused to hEPO was particularly well-suited for purification of the recombinant hormone based on immunoaffinity. Subsequent lectin chromatography allowed enrichment of exclusively sialylated rhEPO. All plant-derived glycoforms exhibited high biological activity as determined by a cell-based receptor-binding assay. The generation of rhEPO carrying largely homogeneous glycosylation profiles (GnGnXF, GnGn, and NaNa) will facilitate further investigation of functionalities with potential implications for medical applications.
Collapse
Affiliation(s)
- Jakub Jez
- Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences, Muthgasse, Vienna, Austria
| | | | | | | | | | | | | |
Collapse
|
31
|
Costa AR, Rodrigues ME, Henriques M, Oliveira R, Azeredo J. Glycosylation: impact, control and improvement during therapeutic protein production. Crit Rev Biotechnol 2013; 34:281-99. [PMID: 23919242 DOI: 10.3109/07388551.2013.793649] [Citation(s) in RCA: 104] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The emergence of the biopharmaceutical industry represented a major revolution for modern medicine, through the development of recombinant therapeutic proteins that brought new hope for many patients with previously untreatable diseases. There is a ever-growing demand for these therapeutics that forces a constant technological evolution to increase product yields while simultaneously reducing costs. However, the process changes made for this purpose may also affect the quality of the product, a factor that was initially overlooked but which is now a major focus of concern. Of the many properties determining product quality, glycosylation is regarded as one of the most important, influencing, for example, the biological activity, serum half-life and immunogenicity of the protein. Consequently, monitoring and control of glycosylation is now critical in biopharmaceutical manufacturing and a requirement of regulatory agencies. A rapid evolution is being observed in this context, concerning the influence of glycosylation in the efficacy of different therapeutic proteins, the impact on glycosylation of a diversity of parameters/processes involved in therapeutic protein production, the analytical methodologies employed for glycosylation monitoring and control, as well as strategies that are being explored to use this property to improve therapeutic protein efficacy (glycoengineering). This work reviews the main findings on these subjects, providing an up-to-date source of information to support further studies.
Collapse
Affiliation(s)
- Ana Rita Costa
- IBB - Institute for Biotechnology and Bioengineering, Centre of Biological Engineering, University of Minho, Campus de Gualtar , Braga , Portugal
| | | | | | | | | |
Collapse
|
32
|
Baranyi L, Doering CB, Denning G, Gautney RE, Harris KT, Spencer HT, Roy A, Zayed H, Dropulic B. Rapid Generation of Stable Cell Lines Expressing High Levels of Erythropoietin, Factor VIII, and an Antihuman CD20 Antibody Using Lentiviral Vectors. Hum Gene Ther Methods 2013; 24:214-27. [DOI: 10.1089/hgtb.2013.002] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Affiliation(s)
| | | | | | | | | | - H. Trent Spencer
- Department of Pharmacology, Emory University School of Medicine, Atlanta, GA 30322
| | - Andre Roy
- Lentigen Corporation, Gaithersburg, MD 20878
| | - Hatem Zayed
- Lentigen Corporation, Gaithersburg, MD 20878
| | | |
Collapse
|
33
|
RNAi suppression of β-N-acetylglucosaminidase (BmFDL) for complex-type N-linked glycan synthesis in cultured silkworm cells. Biotechnol Lett 2013; 35:1009-16. [DOI: 10.1007/s10529-013-1183-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2012] [Accepted: 02/27/2013] [Indexed: 10/27/2022]
|
34
|
Okano M, Sato M, Kageyama S. Identification of the long-acting erythropoiesis-stimulating agent darbepoetin alfa in human urine by liquid chromatography–tandem mass spectrometry. Anal Bioanal Chem 2013; 406:1317-29. [DOI: 10.1007/s00216-013-6836-y] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2012] [Revised: 01/25/2013] [Accepted: 02/07/2013] [Indexed: 12/11/2022]
|
35
|
Castilho A, Neumann L, Gattinger P, Strasser R, Vorauer-Uhl K, Sterovsky T, Altmann F, Steinkellner H. Generation of biologically active multi-sialylated recombinant human EPOFc in plants. PLoS One 2013; 8:e54836. [PMID: 23372778 PMCID: PMC3555983 DOI: 10.1371/journal.pone.0054836] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2012] [Accepted: 12/19/2012] [Indexed: 11/29/2022] Open
Abstract
Hyperglycosylated proteins are more stable, show increased serum half-life and less sensitivity to proteolysis compared to non-sialylated forms. This applies particularly to recombinant human erythropoietin (rhEPO). Recent progress in N-glycoengineering of non-mammalian expression hosts resulted in in vivo protein sialylation at great homogeneity. However the synthesis of multi-sialylated N-glycans is so far restricted to mammalian cells. Here we used a plant based expression system to accomplish multi-antennary protein sialylation. A human erythropoietin fusion protein (EPOFc) was transiently expressed in Nicotiana benthamiana ΔXTFT, a glycosylation mutant that lacks plant specific N-glycan residues. cDNA of the hormone was co-delivered into plants with the necessary genes for (i) branching (ii) β1,4-galactosylation as well as for the (iii) synthesis, transport and transfer of sialic acid. This resulted in the production of recombinant EPOFc carrying bi- tri- and tetra-sialylated complex N-glycans. The formation of this highly complex oligosaccharide structure required the coordinated expression of 11 human proteins acting in different subcellular compartments at different stages of the glycosylation pathway. In vitro receptor binding assays demonstrate the generation of biologically active molecules. We demonstrate the in planta synthesis of one of the most complex mammalian glycoforms pointing to an outstanding high degree of tolerance to changes in the glycosylation pathway in plants.
Collapse
Affiliation(s)
- Alexandra Castilho
- Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences, Vienna, Austria
| | - Laura Neumann
- Department of Chemistry, University of Natural Resources and Life Sciences, Vienna, Austria
| | - Pia Gattinger
- Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences, Vienna, Austria
| | - Richard Strasser
- Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences, Vienna, Austria
| | - Karola Vorauer-Uhl
- Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria
| | | | - Friedrich Altmann
- Department of Chemistry, University of Natural Resources and Life Sciences, Vienna, Austria
| | - Herta Steinkellner
- Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences, Vienna, Austria
| |
Collapse
|
36
|
N-glycan analysis of human α1-antitrypsin produced in Chinese hamster ovary cells. Glycoconj J 2012; 30:537-47. [DOI: 10.1007/s10719-012-9453-7] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2012] [Revised: 09/18/2012] [Accepted: 09/19/2012] [Indexed: 10/27/2022]
|
37
|
de Kort BJ, de Jong GJ, Somsen GW. Profiling of erythropoietin products by capillary electrophoresis with native fluorescence detection. Electrophoresis 2012; 33:2996-3001. [DOI: 10.1002/elps.201200303] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2012] [Revised: 06/05/2012] [Accepted: 08/02/2012] [Indexed: 12/22/2022]
|
38
|
Lee JS, Ha TK, Lee SJ, Lee GM. Current state and perspectives on erythropoietin production. Appl Microbiol Biotechnol 2012; 95:1405-16. [DOI: 10.1007/s00253-012-4291-x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2012] [Revised: 07/09/2012] [Accepted: 07/09/2012] [Indexed: 11/25/2022]
|
39
|
Eon-Duval A, Broly H, Gleixner R. Quality attributes of recombinant therapeutic proteins: An assessment of impact on safety and efficacy as part of a quality by design development approach. Biotechnol Prog 2012; 28:608-22. [DOI: 10.1002/btpr.1548] [Citation(s) in RCA: 142] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2012] [Revised: 03/26/2012] [Indexed: 12/12/2022]
|
40
|
Rouiller Y, Périlleux A, Marsaut M, Stettler M, Vesin MN, Broly H. Effect of hydrocortisone on the production and glycosylation of an Fc-fusion protein in CHO cell cultures. Biotechnol Prog 2012; 28:803-13. [PMID: 22535835 DOI: 10.1002/btpr.1530] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2011] [Revised: 02/09/2012] [Indexed: 12/30/2022]
Abstract
Glucocorticoids are known to modulate various cellular functions such as cell proliferation, metabolism, glycosylation, and secretion of many proteins. We tested the effect of hydrocortisone (HC) on cell growth, viability, metabolism, protein production, and glycosylation of an Fc-protein expressing Chinese hamster ovary (CHO) cell culture. HC extended cell viability but impaired cell growth. The inhibitory effect on cell growth was dose-dependent and decreased when the glucocorticoid addition was delayed. When HC was added after 2 or 3 days of culture, an increase in glutamate consumption was observed, which was reversed by the glucocorticoid receptor antagonist mifepristone (Mif). Titer and specific productivity increased in the presence of HC. The increase in titer was only slightly reversed by Mif. On the other hand, Mif by itself induced an increase in titer to a level comparable to or higher than HC. Protein glycosylation was altered by the glucocorticoid in a dose- and time-dependent manner, with a shift to more acidic bands, which correlated with an increase in sialic acid moieties. This increase, which was not linked to a decrease in extracellular sialidase activity in HC-treated cultures, was reversed by Mif. Predictive models based on design of experiments enabled the definition of optimal conditions for process performance in terms of viability and titer and for the quality of the Fc-fusion protein in terms of glycosylation. The data obtained suggest a use of glucocorticoids for commercial production of Fc-fusion proteins expressed in CHO cells.
Collapse
Affiliation(s)
- Yolande Rouiller
- Merck Serono SA, Corsier-sur-Vevey, Biotech Process Sciences, ZI B, CH-1809 Fenil-sur-Corsier, Switzerland.
| | | | | | | | | | | |
Collapse
|
41
|
Ghaderi D, Zhang M, Hurtado-Ziola N, Varki A. Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol Genet Eng Rev 2012; 28:147-75. [DOI: 10.5661/bger-28-147] [Citation(s) in RCA: 241] [Impact Index Per Article: 20.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
42
|
Nett JH, Gomathinayagam S, Hamilton SR, Gong B, Davidson RC, Du M, Hopkins D, Mitchell T, Mallem MR, Nylen A, Shaikh SS, Sharkey N, Barnard GC, Copeland V, Liu L, Evers R, Li Y, Gray PM, Lingham RB, Visco D, Forrest G, DeMartino J, Linden T, Potgieter TI, Wildt S, Stadheim TA, d'Anjou M, Li H, Sethuraman N. Optimization of erythropoietin production with controlled glycosylation-PEGylated erythropoietin produced in glycoengineered Pichia pastoris. J Biotechnol 2011; 157:198-206. [PMID: 22100268 DOI: 10.1016/j.jbiotec.2011.11.002] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2011] [Revised: 10/31/2011] [Accepted: 11/02/2011] [Indexed: 10/15/2022]
Abstract
Pichia pastoris is a methylotropic yeast that has gained great importance as an organism for protein expression in recent years. Here, we report the expression of recombinant human erythropoietin (rhEPO) in glycoengineered P. pastoris. We show that glycosylation fidelity is maintained in fermentation volumes spanning six orders of magnitude and that the protein can be purified to high homogeneity. In order to increase the half-life of rhEPO, the purified protein was coupled to polyethylene glycol (PEG) and then compared to the currently marketed erythropoiesis stimulating agent, Aranesp(®) (darbepoetin). In in vitro cell proliferation assays the PEGylated protein was slightly, and the non-PEGylated protein was significantly more active than comparator. Pharmacodynamics as well as pharmacokinetic activity of PEGylated rhEPO in animals was comparable to that of Aranesp(®). Taken together, our results show that glycoengineered P. pastoris is a suitable production host for rhEPO, yielding an active biologic that is comparable to those produced in current mammalian host systems.
Collapse
|
43
|
Kausar H, Gull S, Ijaz B, Ahmad W, Sarwar MT, Iqbal Z, Nawaz Z, Riazuddin S, Hassan S. Huh-7 cell line as an alternative cultural model for the production of human like erythropoietin (EPO). J Transl Med 2011; 9:186. [PMID: 22040235 PMCID: PMC3228713 DOI: 10.1186/1479-5876-9-186] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2011] [Accepted: 11/01/2011] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND AND AIMS Erythropoietin (EPO) is a glycoprotein hormone which is required to regulate the production of red blood cells. Deficiency of EPO is known to cause anemia in chronically infected renal patients and they require regular blood transfusion. Availability of recombinant EPO has eliminated the need for blood transfusion and now it is extensively used for the treatment of anemia. Glycosylation of erythropoietin is essential for its secretion, stability, protein conformation and biological activity. However, maintenance of human like glycosylation pattern during manufacturing of EPO is a major challenge in biotechnology. Currently, Chinese hamster ovary (CHO) cell line is used for the commercial production of erythropoietin but this cell line does not maintain glycosylation resembling human system. With the trend to eliminate non-human constituent from biopharmaceutical products, as a preliminary approach, we have investigated the potential of human hepatoma cell line (Huh-7) to produce recombinant EPO. MATERIALS AND METHODS Initially, the secretory signal and Kozak sequences was added before the EPO mature protein sequence using overlap extension PCR technique. PCR-amplified cDNA fragments of EPO was inserted into mammalian expression vector under the control of the cytomegalovirus (CMV) promoter and transiently expressed in CHO and Huh-7 cell lines. After RT-PCR analysis, ELISA and Western blotting was performed to verify the immunochemical properties of secreted EPO. RESULTS Addition of secretory signal and Kozak sequence facilitated the extra-cellular secretion and enhanced the expression of EPO protein. Significant expression (P < 0.05) of EPO was observed in the medium from Huh-7 cell line. CONCLUSION Huh-7 cell line has a great potential to produce glycosylated EPO, suggesting the use of this cell line to produce glycoproteins of the therapeutic importance resembling to the natural human system.
Collapse
Affiliation(s)
- Humera Kausar
- Centre of Excellence in Molecular Biology, University of the Punjab, Lahore Pakistan
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Glycan analysis of glycoprotein pharmaceuticals: Evaluation of analytical approaches to Z number determination in pharmaceutical erythropoietin products. Biologicals 2011; 39:396-403. [DOI: 10.1016/j.biologicals.2011.08.012] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2011] [Revised: 08/02/2011] [Accepted: 08/21/2011] [Indexed: 11/19/2022] Open
|
45
|
Bristow AF. Assignment of quantities to biological medicines: an old problem re-discovered. PHILOSOPHICAL TRANSACTIONS. SERIES A, MATHEMATICAL, PHYSICAL, AND ENGINEERING SCIENCES 2011; 369:4004-4013. [PMID: 21930562 DOI: 10.1098/rsta.2011.0175] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
A distinction exists between 'chemical' and 'biological' medicines. While, from antiquity, both organic and inorganic substances had been used in therapy, developing chemical sciences were inapplicable to materials extracted from natural sources, and the active principles could be neither identified nor characterized. The distinction between biological medicines or 'biologicals' grew out of this realization. Such 'biologicals' in clinical use were, however, variable in efficacy and in safety, and controlling the strength or quality was necessary. Without information on what biological medicines are, it was necessary to quantify what they do, and such medicines were quantified using systems based on biological responses (bioassays) in animals, organs or cells. Bioassays are defined in terms of an external standard rather than in absolute terms, and depend on a number of key assumptions: the need to assay 'like against like', the desirability of making the assay principle relevant to the intended clinical effect in man, and the importance of appropriate statistical models of design and analysis. The science of 'biological standardization' has kept pace with developments in medicine and continues to allow the use of biological medicines in man to be controlled on the basis of common measurement systems.
Collapse
Affiliation(s)
- Adrian F Bristow
- National Institute for Biological Standards and Control (Health Protection Agency), Blanche Lane, South Mims, Potters Bar, Herts EN6 3QG, UK.
| |
Collapse
|
46
|
Castilho A, Gattinger P, Grass J, Jez J, Pabst M, Altmann F, Gorfer M, Strasser R, Steinkellner H. N-glycosylation engineering of plants for the biosynthesis of glycoproteins with bisected and branched complex N-glycans. Glycobiology 2011; 21:813-23. [PMID: 21317243 PMCID: PMC3091529 DOI: 10.1093/glycob/cwr009] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2010] [Revised: 01/17/2011] [Accepted: 01/17/2011] [Indexed: 01/07/2023] Open
Abstract
Glycoengineering is increasingly being recognized as a powerful tool to generate recombinant glycoproteins with a customized N-glycosylation pattern. Here, we demonstrate the modulation of the plant glycosylation pathway toward the formation of human-type bisected and branched complex N-glycans. Glycoengineered Nicotiana benthamiana lacking plant-specific N-glycosylation (i.e. β1,2-xylose and core α1,3-fucose) was used to transiently express human erythropoietin (hEPO) and human transferrin (hTF) together with modified versions of human β1,4-mannosyl-β1,4-N-acetylglucosaminyltransferase (GnTIII), α1,3-mannosyl-β1,4-N-acetylglucosaminyltransferase (GnTIV) and α1,6-mannosyl-β1,6-N-acetylglucosaminyltransferase (GnTV). hEPO was expressed as a fusion to the IgG-Fc domain (EPO-Fc) and purified via protein A affinity chromatography. Recombinant hTF was isolated from the intracellular fluid of infiltrated plant leaves. Mass spectrometry-based N-glycan analysis of hEPO and hTF revealed the quantitative formation of bisected (GnGnbi) and tri- as well as tetraantennary complex N-glycans (Gn[GnGn], [GnGn]Gn and [GnGn][GnGn]). Co-expression of GnTIII together with GnTIV and GnTV resulted in the efficient generation of bisected tetraantennary complex N-glycans. Our results show the generation of recombinant proteins with human-type N-glycosylation at great uniformity. The strategy described here provides a robust and straightforward method for producing mammalian-type N-linked glycans of defined structures on recombinant glycoproteins, which can advance glycoprotein research and accelerate the development of protein-based therapeutics.
Collapse
Affiliation(s)
| | | | - Josephine Grass
- Department of Chemistry, University of Natural Resources and Life Sciences, A-1190 Vienna, Austria
| | - Jakub Jez
- Department of Applied Genetics and Cell Biology
| | - Martin Pabst
- Department of Chemistry, University of Natural Resources and Life Sciences, A-1190 Vienna, Austria
| | - Friedrich Altmann
- Department of Chemistry, University of Natural Resources and Life Sciences, A-1190 Vienna, Austria
| | | | | | | |
Collapse
|
47
|
Jung Y, Jung MY, Park JH, Jung GC, Hong YS, Yeom CH, Lee S. Production of human hyaluronidase in a plant-derived protein expression system: plant-based transient production of active human hyaluronidase. Protein Expr Purif 2010; 74:181-8. [PMID: 20558297 DOI: 10.1016/j.pep.2010.06.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2010] [Revised: 06/05/2010] [Accepted: 06/08/2010] [Indexed: 01/23/2023]
Abstract
Four types of human hyaluronidases (rHuHyal-1, -2, -3 and -4) were transiently expressed and purified from Nicotiana benthamiana, and their biochemical characteristics were analyzed. The recombinant HuHyals were expressed via agrobacteria-mediated infiltration and generated and expressed in terms of micrograms per 5 leaves of N. benthamiana. Expressed recombinant HuHyals were purified using a His(6) tagging system and Ni column chromatography, respectively, at pH 8.0, after which the purified rHuHyals were concentrated for additional biochemical analyses. The four types of rHuHyals were allowed to react with hyaluronic acids and chondroitin sulfates. The biochemical properties of rHuHyal-1 fit those of the commercially available Hyal, PH-20, which was extracted from animal testes under acidic conditions (pH 3.5). However, rHuHyal-1 evidenced activity levels 2 to 6-fold greater than the three other rHuHyals (rHuHyal-2, -3 and -4) at pH 3.5. However, only rHuHyal-4 exhibited chondroitinase activity with both 6-S-chondroitin sulfate (chondroitin sulfate C) and 4-S-chondroitin sulfate (chondroitin sulfate A) as standard substrates. The results of zymography demonstrated that recombinant HuHyal 1 was modified by glycosylation, but Escherichia coli Hyal was not. This result demonstrated that plant-based rHuHyal was functionally active and evidenced biochemical characteristics and post-translational protein modifications similar to those of animal testis-derived Hyal.
Collapse
Affiliation(s)
- Yuchul Jung
- Department of Genetic Engineering, Sungkyunkwan University, Suwon, Republic of Korea
| | | | | | | | | | | | | |
Collapse
|
48
|
Selectivity of ligand-binding assays in relationship to the measurement of biologics: how much does it matter? Bioanalysis 2010; 2:1525-30. [DOI: 10.4155/bio.10.112] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
|
49
|
Singh SK. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 2010; 100:354-87. [PMID: 20740683 DOI: 10.1002/jps.22276] [Citation(s) in RCA: 250] [Impact Index Per Article: 17.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2009] [Revised: 05/13/2010] [Accepted: 05/24/2010] [Indexed: 12/12/2022]
Abstract
All protein therapeutics have the potential to be immunogenic. Several factors, including patient characteristics, disease state, and the therapy itself, influence the generation of an immune response. Product-related factors such as the molecule design, the expression system, post-translational modifications, impurities, contaminants, formulation and excipients, container, closure, as well as degradation products are all implicated. However, a critical examination of the available data shows that clear unequivocal evidence for the impact of these latter factors on clinical immunogenicity is lacking. No report could be found that clearly deconvolutes the clinical impact of the product attributes on patient susceptibility. Aggregation carries the greatest concern as a risk factor for immunogenicity, but the impact of aggregates is likely to depend on their structure as well as on the functionality (e.g., immunostimulatory or immunomodulatory) of the therapeutic. Preclinical studies are not yet capable of assessing the clinically relevant immunogenicity potential of these product-related factors. Simply addressing these risk factors as part of product development will not eliminate immunogenicity. Minimization of immunogenicity has to begin at the molecule design stage by reducing or eliminating antigenic epitopes and building in favorable physical and chemical properties.
Collapse
Affiliation(s)
- Satish Kumar Singh
- Pfizer, Inc., BioTherapeutics Pharmaceutical Sciences, Pharmaceutical Research and Development, Chesterfield, Missouri 63017, USA.
| |
Collapse
|
50
|
Montesino R, Gil J, González LJ, Zamora Y, Royle L, Rudd PM, Dwek RA, Harvey DJ, Cremata JA. The N-glycosylation of classical swine fever virus E2 glycoprotein extracellular domain expressed in the milk of goat. Arch Biochem Biophys 2010; 500:169-80. [DOI: 10.1016/j.abb.2010.05.006] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2010] [Revised: 05/05/2010] [Accepted: 05/05/2010] [Indexed: 10/19/2022]
|